Trial Profile
Phase I Study of Irinotecan and Erlotinib in Patients with Erlotinib Failure for EGFR Mutations Non-Small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 30 Jun 2011
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Irinotecan (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 30 Jun 2011 New trial record